European Patent Convention

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Retrieved on: 
Wednesday, April 10, 2024
Malignancy, Spanish mythology, State university system, Patient, Sale, Renal cell carcinoma, Clinical trial, Neoplasm, Therapy, Depreciation, HPHA, USD, Marketing, GLP, Health, Research, ATACS, EPO, Immune system, ADC, BLA, ATAC, Food, Biologics license application, Disease, Magenta, Multiple myeloma, AACR, GCC, Annual report, FDA, Diagnosis, EUR, Supervisory board, Accounting, PET, EDT, Spacecraft, Amanitin, European Patent Convention, Patent, Eli Lilly and Company, Binghamton University, Pharmaceutical industry

Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).

Key Points: 
  • Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).
  • As a result, Heidelberg Pharma lost sales revenue in the low single-digit millions for the 2023 financial year.
  • In April 2023, Heidelberg Pharma signed a termination agreement with Magenta under which all licensed ATAC rights and some Magenta patents were assumed by Heidelberg Pharma.
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

Medigene AG Secures European Patent for its iM-TCR Technology

Retrieved on: 
Thursday, April 4, 2024
TCR, Patent, CSO, Research, Cell death, European Patent Convention, Safety

---  end of press release  ---

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies.
  • “Over the past years we have conscientiously built an extensive international intellectual property portfolio across major markets, which we expect will provide a significant competitive advantage.
  • Each technology we design and develop aims to enhance efficacy and mitigate safety risk to the patient and is based on our extensive immunology research and experience.
  • We are pleased to receive this latest patent grant for our iM-TCR technology from the European Patent Office, which complements our recently granted patent in Japan,” said Dolores Schendel, CSO at Medigene.

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Retrieved on: 
Wednesday, April 3, 2024
Growth, Risk, Patient, EPO, European Patent Convention, Patent, Family, Professional corporation, SPCS, Triglyceride, Pharmaceutical industry

In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.

Key Points: 
  • In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.
  • Additional independent patent applications from this family remain pending, which when granted, will further reinforce VAZKEPA’s exclusivity in Europe until April 2039.
  • Additionally, in November 2023, Amarin successfully defended a separate patent containing claims covering VAZKEPA in Europe from third-party opposition.
  • At the conclusion of that opposition, the EPO found all claims for Amarin’s 2033 VAZKEPA patent to be valid.

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Retrieved on: 
Monday, April 1, 2024
Administration, Annual report, B cell, Obesity, Development, Cell, Patent, Library, Visual analogue scale, Patient, DSM-IV codes, Data monitoring committee, Form 10-K, Security (finance), Functional, Adipocyte, Type 2 diabetes, Small business, Investment, Research and development, NOA, European Patent Convention, Safety, Infrared spectroscopy correlation table, Orthopaedic Research Society, Annual general meeting, Pharmaceutical industry

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.

Key Points: 
  • MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.
  • The annual report can be accessed on the SEC's website at www.sec.gov , and on the Company's website at www.biorestorative.com under "SEC Filing" in the Investors and Media section.
  • A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States.
  • At December 31, 2023, BioRestorative had cash, cash equivalents and investments in marketable securities of $11.07 million.

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Retrieved on: 
Monday, March 25, 2024
Orphan drug, Primary sclerosing cholangitis, Inflammation, Fast Track, European Patent Organisation, Antibody, PSC, Liver, Liver transplantation, Doctor of Philosophy, CCL24, Fibrosis, Treatment, Therapy, European Patent Convention, CMMB, Patent, Use, Hepatology, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

Key Points: 
  • CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
  • Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
  • The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic (liver) diseases, including PSC.
  • Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation.

Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office

Retrieved on: 
Tuesday, March 19, 2024
Health, Informatics, PHG, Research, Software, AI, EPO, European Patent Convention, Patent, Intellectual property, Medtech, AEX, Medical device

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO).

Key Points: 
  • Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO).
  • Building on more than 130 years of innovation, Philips’ extensive global R&D programs and collaborations position the company at the forefront of health technology innovation.
  • With 607 MedTech patent applications in 2023, Philips is the second largest applicant in EPO's Patent Index 2023 in the field of medical technology.
  • In total, Philips contributed 1,299 patent applications across various domains, solidifying its standing among the top 10 patent filers overall.

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Retrieved on: 
Friday, March 15, 2024
The Orange Book, Agitation, Patent, Intelligence, Patient, Tablet, Heel, EPO, Orange Book, Therapy, European Patent Convention, Dexmedetomidine, FDA, Dementia, Pharmaceutical industry

The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.

Key Points: 
  • The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.
  • The patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and tablets, at dexmedetomidine doses ranging from 3 mcg to 100 mcg.
  • 17/496,470 with claims pertaining to methods of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form.
  • The patent, when issued, is expected to have an expiration date of July 17, 2040, subject to patent term adjustment, patent term extension, and terminal disclaimers.

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
Research, Conference, Immunotherapy, Patient, Sale, Viral, Society, Chemokine, Therapy, Cytokine, European Patent Convention, Safety, Cryptocurrency

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.
  • General and administrative expenses for the three-month periods ended December 31, 2023 and 2022, were $2.2 million.
  • Loss per share for the twelve-month period ended December 31, 2023 was $1.83, compared with $1.73 for the twelve-month period ended December 31, 2022.
  • There was no net cash provided by or used in financing activities for the twelve-month periods ended December 31, 2023 and 2022.

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the European Patent Office

Retrieved on: 
Tuesday, April 2, 2024
Salt, Progression-free survival, Patient, EPO, MD, Pembrolizumab, Human, Therapy, European Patent Convention, Safety, Pharmacokinetics, Randomized controlled trial, Patent, EP, Animal, SRR, Pharmaceutical industry

HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.

Key Points: 
  • European Patent 3,823,617 Issued on March 6, 2024
    HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.
  • "We are extremely pleased that the EPO has issued this composition of matter patent," commented Patrick Mooney, MD, CEO of Linnaeus.
  • As we continue to collect very promising data from our clinical trials with LNS8001, we will continue to prosecute the claims in this patent worldwide."
  • The study will enroll 135 patients who will be selected based on a predictive biomarker and then randomized to receive LNS8801 alone, LNS8801 and pembrolizumab, or physician's choice therapy.

Bound2B successfully obtains preliminary injunction against Xolution Germany GmbH and its re-sealable XO closing device on beverage cans

Retrieved on: 
Thursday, March 21, 2024
Federal Patent Court, District court, Injunction, XO, Judgement, European Patent Convention, Patent, EP, Court

RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.  The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.

Key Points: 
  • in particular its XO closing device, in Germany
    RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.
  • The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.
  • In 2020, Bound2B initiated patent infringement proceedings before the District Court of Düsseldorf based on EP 930 against Xolution GmbH, who manufactured, advertised, and delivered the XO closing device.
  • In order to prevent further offering and selling of the XO closing device in Germany, Bound2B filed for urgent proceedings and asked the Düsseldorf Court to immediately issue a preliminary injunction against Xolution Germany GmbH as well as its Managing Director, Mr. von Rettberg.